SEC Company Response from Dianthus Therapeutics, (DNTH) — Aug 14, 2019
Dianthus Therapeutics, Inc. /DE/ (DNTH) (CIK 0001690585)
Date: Aug. 14, 2019 · CIK: 0001690585 · Accession: 0001193125-19-221210
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-233127
Letter
Magenta Therapeutics, Inc.
100 Technology Square
Cambridge, MA 02139
August 14, 2019
Via EDGAR Transmission
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: Magenta Therapeutics, Inc.: Registration Statement on Form S-3 filed August 8, 2019 (File No. 333-233127)
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Magenta Therapeutics, Inc. (the “Company”) hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to August 19, 2019, at 4:01 pm Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.
If you have any questions regarding this request, please contact William Collins of Goodwin Procter LLP at (617) 570-1447.
Sincerely,
Magenta Therapeutics, Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP Magenta Therapeutics, Inc. 100 Technology Square Cambridge, MA 02139 August 14, 2019 Via EDGAR Transmission United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Magenta Therapeutics, Inc.: Registration Statement on Form S-3 filed August 8, 2019 (File No. 333-233127) Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Magenta Therapeutics, Inc. (the “Company”) hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to August 19, 2019, at 4:01 pm Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act. If you have any questions regarding this request, please contact William Collins of Goodwin Procter LLP at (617) 570-1447. Sincerely, Magenta Therapeutics, Inc. /s/ Jason Gardner Jason Gardner President and Chief Executive Officer cc: Zoran Zdraveski, Secretary and Chief Legal Officer, Magenta Therapeutics, Inc. William Collins, Esq., Goodwin Procter LLP Mitchell S. Bloom, Esq., Goodwin Procter LLP